Tracking a promising leukemia Drug's Real-World impact
NCT ID NCT07117136
Summary
This study aims to understand how well the drug blinatumomab works for adults with B-cell acute lymphoblastic leukemia (B-ALL) in real-world medical settings across the United States. Researchers will collect data from 200 patients who have received this treatment as part of their standard care. The goal is to see how effective the drug is when used alongside various common chemotherapy regimens, building on promising results from earlier clinical trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.